Results 71 to 80 of about 1,221,475 (381)

Cellular liquid biopsy provides unique chances for disease monitoring, preclinical model generation and therapy adjustment in rare salivary gland cancer patients

open access: yesMolecular Oncology, EarlyView.
We quantified and cultured circulating tumor cells (CTCs) of 62 patients with various cancer types and generated CTC‐derived tumoroid models from two salivary gland cancer patients. Cellular liquid biopsy‐derived information enabled molecular genetic assessment of systemic disease heterogeneity and functional testing for therapy selection in both ...
Nataša Stojanović Gužvić   +31 more
wiley   +1 more source

Immunohistochemistry in Ophthalmology

open access: yesDelhi Journal of Ophthalmology, 2017
Immunohistochemistry is a pathological technique wherein the distribution of a particular protein or lipid antigen in a tissue specimen is determined using a combination of immunological, histochemical and biochemical principles.
Smriti Nagpal Gupta   +4 more
doaj   +1 more source

Automated segmentation of rheumatoid arthritis immunohistochemistry stained synovial tissue [PDF]

open access: yesarXiv, 2023
Rheumatoid Arthritis (RA) is a chronic, autoimmune disease which primarily affects the joint's synovial tissue. It is a highly heterogeneous disease, with wide cellular and molecular variability observed in synovial tissues. Over the last two decades, the methods available for their study have advanced considerably.
arxiv  

HAGE, a cancer/testis antigen expressed at the protein level in a variety of cancers [PDF]

open access: yes, 2010
The search for novel tumour antigens that are either uniquely expressed or over-expressed in a wide variety of tumours is still ongoing. Because of their expression in a broad spectrum of cancers and limited expression in normal tissues, cancer/testis ...
Badoual, C   +6 more
core  

Updated recommendations for HER2 testing in the UK [PDF]

open access: yes, 2004
This paper serves to update previously published guidance on rationale and methodology for HER2 laboratory testing following the recommendation for the use of HER2 targeted treatment in the management of advanced breast cancer in the UK.
Bartlett, J.M.S.   +8 more
core   +2 more sources

Vertical inhibition of p110α/AKT and N‐cadherin enhances treatment efficacy in PIK3CA‐aberrated ovarian cancer cells

open access: yesMolecular Oncology, Volume 19, Issue 4, Page 1132-1154, April 2025.
PIK3CA amplification and PIK3CA mutation enhance ovarian tumorigenicity through an activation of AKT, which phosphorylates YAP at Ser127. This Ser127 phosphorylation leads to the retention of YAP in the cytoplasm and triggers RAC1 activity, promoting cell migration. Additionally, AKT activation increases expression of N‐cadherin, which further enhances
Shibo Zhang   +6 more
wiley   +1 more source

OUR EXPERIENCE OF IMMUNOHISTOCHEMICAL ASSAY IN BREAST CANCER

open access: yesПаёми Сино, 2020
Objective: Analysis of the first experience of immunohistochemical (IHC) diagnostics of breast cancer (BC) in the Republic of Tajikistan for 2018- 2020. Methods: The results of the IHC study of tumor samples obtained by trephine biopsy in 142 patients
S.R. RASULOV, SH.A. VASIKHOV
doaj   +1 more source

Non-specific binding of antibodies in immunohistochemistry: Fakes and facts [PDF]

open access: yes, 2011
Protocols for blocking non-specific antibody (Ab) binding in immunohistochemistry are based on rather contradictory and outdated reports. This prompted us to prove, whether non-specific Ab binding may really lead to unwanted background staining in ...
Igor Buchwalow   +3 more
core   +1 more source

Immunolocalization of KATP channel subunits in mouse and rat cardiac myocytes and the coronary vasculature. [PDF]

open access: yes, 2005
BACKGROUND: Electrophysiological data suggest that cardiac KATP channels consist of Kir6.2 and SUR2A subunits, but the distribution of these (and other KATP channel subunits) is poorly defined.
Artman, M   +13 more
core   +3 more sources

Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab

open access: yesApplied immunohistochemistry & molecular morphology (Print), 2019
Cancer immunotherapies, such as atezolizumab, are proving to be a valuable therapeutic strategy across indications, including non–small cell lung cancer (NSCLC) and urothelial cancer (UC).
B. Vennapusa   +19 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy